{"product_id":"conmed-bcg-matrix","title":"Conmed Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDownload Your Competitive Advantage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eConmed’s BCG Matrix snapshot highlights where its key product lines sit amid shifting medical-device markets—identifying potential Stars in surgical tools, Cash Cows in established consumables, and areas that may be Dogs or Question Marks needing strategic review. This preview teases quadrant-level positioning and high-level implications; purchase the full BCG Matrix to get a complete Word report and Excel summary with precise placements, data-backed recommendations, and an actionable roadmap to optimize portfolio, allocate capital, and drive growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAirSeal System Platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAirSeal System Platform remains CONMED’s star product, sustaining the premier integrated access position for robotic and laparoscopic surgery by keeping stable pneumoperitoneum; CONMED reported \u0026gt;40% share in advanced insufflation in 2024 and \u0026gt;$120m system-related revenue that year.\u003c\/p\u003e\n\u003cp\u003eWith robotic-assisted procedures growing ~12% CAGR through 2025, AirSeal benefits from double-digit market expansion and high attach rates for disposables, boosting recurring revenue and margin upside.\u003c\/p\u003e\n\u003cp\u003eAirSeal functions as a gateway for CONMED disposables; CONMED increased global sales training spend by ~15% in 2024 to protect share, and continued investment is needed to sustain leadership.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBuffalo Filter Smoke Evacuation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRegulatory mandates in the US, EU, and China since 2023 have pushed hospitals to adopt smoke evacuation; WHO and AORN guidance cite surgical plume risks, driving annual market growth ~12% and hospital procurement cycles rising to 3–5 years.\u003c\/p\u003e\n\u003cp\u003eCONMED holds a leading share (~28% global, 35% US 2025 estimate) in smoke evacuation with Buffalo Filter, a high-margin line yielding recurring filter\/tubing revenue \u0026gt;$60M ARR and ~55% gross margin.\u003c\/p\u003e\n\u003cp\u003eRapid segment expansion and compliance-driven replacement create a large untapped account base; aggressive field marketing and bundle pricing could raise penetration by 10–15% and add $8–12M EBITDA within 12–18 months.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBioBrace Soft Tissue Reinforcement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAcquired via Biorez in 2021, BioBrace Soft Tissue Reinforcement blends a collagen scaffold with high-strength fibers, targeting the $3.5B global sports medicine biologics market (2025 estimate) and the growing tendon\/ligament repair segment projected at 6.8% CAGR to 2030.\u003c\/p\u003e\n\u003cp\u003eIt fills a clinical gap by offering mechanical support plus biologic healing—critical as active-patient procedures rose ~12% from 2019–2024—so CONMED positions it as a Star in the BCG matrix.\u003c\/p\u003e\n\u003cp\u003eCommercial upside depends on robust clinical trials and surgeon training; CONMED reported $1.4B revenue in 2024, allowing targeted investment in evidence generation and education to scale adoption.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInSet Robotic Tissue Retrieval\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eInSet Robotic Tissue Retrieval targets the growing niche of specimen retrieval for robotic surgery, where CONMED booked ~6% revenue growth in its soft-tissue portfolio in FY2024 and reports double-digit adoption rates in U.S. robotic ORs year-over-year.\u003c\/p\u003e\n\u003cp\u003eDemand outpaced manual alternatives as robotic procedures rose ~12% CAGR (2019–2024); CONMED is investing \u0026gt;$20M (2024–2025) to scale production and surgeon training to stay preferred during the laparoscopic-to-robotic shift.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket: robotic procedures +12% CAGR (2019–2024)\u003c\/li\u003e\n\u003cli\u003eCONMED spend: \u0026gt;$20M (2024–2025)\u003c\/li\u003e\n\u003cli\u003eProduct growth: portfolio ~6% revenue rise in FY2024\u003c\/li\u003e\n\u003cli\u003eAdoption: double-digit annual increase in U.S. robotic OR use\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eY-Knot Advanced Anchor Systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eY-Knot Advanced Anchor Systems' all-soft anchor lets surgeons use smaller drill holes while delivering higher fixation strength, shifting the sports medicine fixation norm and supporting Conmed's star placement in orthopedics.\u003c\/p\u003e\n\u003cp\u003eMarket share stays high as U.S. outpatient surgery centers grew 8% in 2024, boosting arthroscopic volume; Conmed's anchor line benefits from this tailwind, contributing an estimated $85–95M annual revenue in 2025-range sales for the category.\u003c\/p\u003e\n\u003cp\u003eSustained R\u0026amp;D spending of ~5–7% of product-line revenue is needed to block copycat anchors; competitors are already filing smaller-footprint patents and cutting prices, so keep iterative design and clinical-data updates.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSmaller drill holes = higher fixation strength\u003c\/li\u003e\n\u003cli\u003eOutpatient center growth +8% (2024) raises arthroscopy volume\u003c\/li\u003e\n\u003cli\u003eEstimated $85–95M revenue for anchor category (2025-range)\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D at 5–7% revenue to defend IP and clinical lead\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh‑margin devices (AirSeal, BioBrace, InSet, Y‑Knot) drive recurring revenue, $8–12M EBITDA upswing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStars: AirSeal, BioBrace, InSet, Y-Knot lead fast-growing segments with high margins and recurring revenue; AirSeal \u0026gt;$120M systems (2024), \u0026gt;40% advanced insufflation share, filters \u0026gt;$60M ARR; CONMED total revenue $1.4B (2024); robotic procedures ~12% CAGR (2019–2025); anchor category ~$85–95M (2025 est); targeted investments ($20M–$120M range) can grow EBITDA $8–12M.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2024–25 Key\u003c\/th\u003e\n\u003cth\u003eRevenue\/ARR\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAirSeal\u003c\/td\u003e\n\u003ctd\u003e40% share\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$120M\u003c\/td\u003e\n\u003ctd\u003eFilters \u0026gt;$60M ARR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBioBrace\u003c\/td\u003e\n\u003ctd\u003esports med market $3.5B (2025)\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003ctd\u003eNeeds trials\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInSet\u003c\/td\u003e\n\u003ctd\u003e$20M capex (2024–25)\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003ctd\u003eDouble-digit OR adoption\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eY-Knot\u003c\/td\u003e\n\u003ctd\u003eOutpatient +8% (2024)\u003c\/td\u003e\n\u003ctd\u003e$85–95M (2025 est)\u003c\/td\u003e\n\u003ctd\u003eR\u0026amp;D 5–7% rev\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eComprehensive BCG Matrix for Conmed: quadrant-specific strengths, threats, investment\/hold\/divest guidance, and trend-driven strategic recommendations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page Conmed BCG Matrix placing each business unit in a quadrant for quick strategic review\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeneral Electrosurgery Generators and Pencils\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCONMED’s electrosurgery generators and disposable pencils are cash cows: the global electrosurgery device market was valued at $4.2B in 2024 with ~2% CAGR, and CONMED holds an estimated low-double-digit share in reusable generators and single-use pencils, driving high-volume, low-marketing-margin sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTraditional Endoscopic Snares and Clips\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe gastroenterology portfolio’s snares and hemostasis clips support ~15–20M US endoscopy\/colonoscopy procedures yearly (2024 CMS\/ASGE mix), driving replacement rates near 1.0 per procedure and steady consumable spend; that yields predictable revenue of roughly $40–60M for CONMED’s GI consumables in 2024 (internal estimate based on company disclosures).\u003c\/p\u003e\n\u003cp\u003eThese products sit in a mature, low-growth market but deliver high margins because CONMED uses existing distributor channels and hospital DME contracts, keeping incremental marketing capex near zero and protecting EBITDA contribution; operating leverage makes them classic cash cows.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHall Powered Orthopedic Instruments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe Hall Powered Orthopedic Instruments brand, a legacy name in powered surgical tools for bone cutting and drilling, delivers steady revenue—CONMED reported service and replacement parts for instrumentation contributed roughly $95M of recurring revenue in 2024, supporting gross margins near 58%. The large- and small-bone power tool market is mature, with low single-digit growth, yet Hall’s loyal installed base sustains high aftermarket attach rates and makes this unit a classic cash cow needing only minor product updates to retain its industry-standard position.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMechanical Resection Shaver Blades\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMechanical resection shaver blades are a cash cow for Conmed: disposables used in arthroscopy deliver high margins and steady volume, with global arthroscopic procedures ~6.5M annually (2024 est.), driving predictable recurring revenue of roughly $150–200M per year for disposables within the ortho portfolio.\u003c\/p\u003e\n\u003cp\u003eInnovation has slowed, so R\u0026amp;D spend is low while bundled sales with capital shaver consoles lock customers in, raising lifetime value and creating a strong barrier to entry that limits competitor share gains.\u003c\/p\u003e\n\u003cp\u003eMinimal promo is needed; blades leverage installed base utilization rates (typical blade per case) to sustain long-term profitability and cash generation.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh-volume disposable: ~6.5M arthroscopies\/yr\u003c\/li\u003e\n\u003cli\u003eEstimated disposables revenue: $150–200M\/yr\u003c\/li\u003e\n\u003cli\u003eHigh margins; low R\u0026amp;D\u003c\/li\u003e\n\u003cli\u003eBundled with consoles → strong lock-in\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStandard Patient Care Electrodes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCONMED’s Standard Patient Care Electrodes (ECG electrodes and cardiac sensors) sit in a large, low-growth hospital commodity market; US hospital ECG electrode spend ~ $420M in 2024 and grew ~1% YoY.\u003c\/p\u003e\n\u003cp\u003eHeavy price competition exists, but CONMED’s scale yields ~15–18% gross margin on electrodes, producing steady cash flow used to pay down corporate debt (net debt ~$330M at 9\/30\/2025) and fund surgical R\u0026amp;D and rollouts.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLarge, low-growth market: ~$420M US spend (2024)\u003c\/li\u003e\n\u003cli\u003eCompany scale → 15–18% gross margin\u003c\/li\u003e\n\u003cli\u003eCash funds debt service: net debt ~$330M (9\/30\/2025)\u003c\/li\u003e\n\u003cli\u003eSupports expansion of surgical product lines and R\u0026amp;D\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCONMED’s high‑margin cash cows: electrosurgery, shavers, GI consumables, ECG electrodes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCONMED’s electrosurgery, Hall power tools, arthroscopy shaver disposables, GI snares\/clips, and ECG electrodes are cash cows: mature markets, low single-digit growth, high margins and recurring consumable sales (2024 est. revenues: electrosurgery ~$150–220M; shaver disposables ~$150–200M; GI consumables $40–60M; electrodes ~$40–45M). These units fund R\u0026amp;D and debt paydown (net debt ~$330M as of 9\/30\/2025).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2024 Rev est\u003c\/th\u003e\n\u003cth\u003eMargin\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eElectrosurgery\u003c\/td\u003e\n\u003ctd\u003e$150–220M\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003eLow marketing capex\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eShaver disposables\u003c\/td\u003e\n\u003ctd\u003e$150–200M\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003eBundled consoles\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGI consumables\u003c\/td\u003e\n\u003ctd\u003e$40–60M\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003ePer-procedure replace\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eECG electrodes\u003c\/td\u003e\n\u003ctd\u003e$40–45M\u003c\/td\u003e\n\u003ctd\u003e15–18%\u003c\/td\u003e\n\u003ctd\u003eCommodity scale\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eConmed BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing is the final Conmed BCG Matrix you'll receive after purchase—no watermarks, no placeholder content, just a fully formatted, analysis-ready report designed for strategic clarity and professional presentation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56748142559609,"sku":"conmed-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/conmed-bcg-matrix.png?v=1772205316","url":"https:\/\/matrixbcg.com\/products\/conmed-bcg-matrix","provider":"MatrixBCG","version":"1.0","type":"link"}